Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543568 · ClinicalTrials.gov registry record · Phase 4
Study for Recalcitrant Age Related Macular Degeneration
A Phase 4 study, sponsored by David M. Brown, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT01543568: Completed Phase 4 study, sponsored by David M. Brown, M.D..
NCT01543568 is a Phase 4 study that has completed, run by David M. Brown, M.D.. The registered enrollment target is 46 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01543568, a Phase 4 study, has completed, sponsored by David M. Brown, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
50 Patients with recalcitrant exudative age-related macular degeneration with a history of retinal or subretinal fluid after multiple intravitreal injections with ranibizumab 0.5mg and subsequently treated with ranibizumab 2.0mg, who are incomplete responders to 2.0mg of ranibizumab.
Interventions
- DRUG aflibercept 2.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-10 |
| Phase | Phase 4 |
What the finished NCT01543568 record still lists
NCT01543568 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which aflibercept 2.0 mg is the first listed.
NCT01543568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01543568 about?
NCT01543568 is a clinical study titled "Study for Recalcitrant Age Related Macular Degeneration". 50 Patients with recalcitrant exudative age-related macular degeneration with a history of retinal or subretinal fluid after multiple intravitreal injections with ranibizumab 0.5mg and subsequently treated with ranibizumab 2.0mg, who are incomplete responders to 2.0mg of ranibizumab.
What is the current status of trial NCT01543568?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2012-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01543568?
The interventions under investigation include: aflibercept 2.0 mg (DRUG).
Who is sponsoring clinical trial NCT01543568?
This trial is sponsored by David M. Brown, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01543568's enrollment target sits among peer trials
46 1348th of 2000 higher than 647 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia